Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Actionable insights into research ...
Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...
Profile Reveals Path to Partner "He has been an incredible asset. He is now one of our key leaders in class actions and complex litigation," said Harley Tropin, Co-Founding partner Kozyak Tropin & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results